ArticleBrain sciences2021
Corticolimbic Modulation via Intermittent Theta Burst Stimulation as a Novel Treatment for Functional Movement Disorder: A Proof-of-Concept Study.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05155059 (Phase II Trial of Non-Invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Non-Invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Treatment of Functional Neurological Disorders.Journal of clinical neurology (Seoul, Korea) · 2026Review
- Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.Current neurology and neuroscience reports · 2026Review
- Functional Movement Disorder: Evolving Mechanisms, Diagnostic Precision, and Personalized Multidisciplinary Care.Movement disorders clinical practice · 2025Review
- Platform Technology for Extended Reality Biofeedback Training Under Operant Conditioning for Functional Limb Weakness: Protocol for the Coproduction of an at-Home Solution (React2Home).JMIR research protocols · 2025Article
- Neurobehavioral therapy in functional seizures: Investigation of mechanism of action with resting-state functional magnetic resonance imaging.Epilepsia · 2025Article
- Functional Movement Disorders and Deep Brain Stimulation: A Review.Neurology. Clinical practice · 2025Review
- Brain network pathophysiology in dystonia.Dystonia (Lausanne, Switzerland) · 2025Article
- Orthodontic considerations for managing patients with functional movement disorders: a narrative review and clinical guide.Frontiers in dental medicine · 2025Review
- Targeting VMPFC-amygdala circuit with TMS in substance use disorder: A mechanistic framework.Addiction biology · 2025Article
- Non-invasive neuromodulation of the right temporoparietal junction using theta-burst stimulation in functional neurological disorder.BMJ neurology open · 2024Article
- Effect of neuroanatomy on corticomotor excitability during and after transcranial magnetic stimulation and intermittent theta burst stimulation.Human brain mapping · 2022Article
- Updates in Functional Movement Disorders: from Pathophysiology to Treatment Advances.Current neurology and neuroscience reports · 2022Review
- Use of non-invasive neurostimulation for rehabilitation in functional movement disorders.Frontiers in rehabilitation sciences · 2022Review
- Neurostimulation for the treatment of functional neurological disorder: A systematic review.Epilepsy & behavior reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Neuroimaging studies suggest that corticolimbic dysfunctions, including increased amygdala reactivity to emotional stimuli and heightened fronto-amygdala coupling, play a central role in the pathophysiology of functional movement disorders (FMD). Transcranial magnetic stimulation (TMS) has the potential to probe and modulate brain networks implicated in neuropsychiatric disorders, including FMD. Therefore, the objective of this proof-of-concept study was to investigate the safety, tolerability and preliminary efficacy of fronto-amygdala neuromodulation via targeted left prefrontal intermittent theta burst stimulation (iTBS) on brain and behavioral manifestations of FMD. Six subjects with a clinically defined diagnosis of FMD received three open-label iTBS sessions per day for two consecutive study visits. Safety and tolerability were assessed throughout the trial. Amygdala reactivity to emotionally valenced stimuli presented during an fMRI task and fronto-amygdala connectivity at rest were evaluated at baseline and after each stimulation visit, together with subjective levels of arousal and valence in response to affective stimuli. The FMD symptom severity was assessed at baseline, during treatment and 24 h after the last iTBS session. Multiple doses of iTBS were well-tolerated by all participants. Intermittent TBS significantly decreased fronto-amygdala connectivity and influenced amygdala reactivity to emotional stimuli. These neurocircuitry changes were associated to a marked reduction in FMD symptom severity. Corticolimbic modulation via iTBS represents a promising treatment for FMD that warrants additional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.